CLSN - CLSN STOCK NEWS

Celsion Corporation (NASDAQ: CLSN) has completed enrollment for its Phase I/II OVATION 2 Study involving 110 patients. The study examines the effects of the IL-12 gene-mediated immunotherapy, GEN-1, combined with neoadjuvant chemotherapy (NACT) in advanced ovarian cancer. Results are expected in late 2023, aiming for a 33% improvement in progression-free survival. Preliminary data show promising safety and efficacy. The company plans to seek FDA breakthrough therapy designation for GEN-1, which has already received fast track designation.

Celsion Corporation (NASDAQ: CLSN) will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 4:30 p.m. Eastern time. The presentation will be accessible live and on-demand through a provided link. The conference is scheduled from September 12-14, allowing for in-person meetings at the Lotte New York Palace Hotel. Celsion focuses on innovative cancer treatments, including immunotherapies and DNA therapies, with a pipeline featuring GEN-1, a DNA-based immunotherapy.

Celsion Corporation (NASDAQ: CLSN) announced that CEO Dr. Corinne Le Goff will present at the H.C. Wainwright 24th Annual Global Investment Conference, held from September 12-14, 2022. Dr. Le Goff's presentation is scheduled for September 13 at 4:00 PM ET at the Lotte New York Palace Hotel. Investors can access a replay of the presentation on the company's website. Celsion is a clinical-stage biotechnology firm focused on innovative cancer treatments, including DNA-based immunotherapies like GEN-1 for ovarian cancer. For further details, visit www.celsion.com.

Celsion Corporation (NASDAQ: CLSN) has announced promising results from its DNA-based PLACCINE vaccine, which demonstrated robust immune responses in a murine model against SARS-CoV-2. The study confirmed that vaccines expressing D614G and Delta spike variants elicited significant IgG and neutralizing antibody responses, achieving 90-95% inhibition of viral load. Executives expressed optimism about further developments in non-human primates later this year. PLACCINE represents a new class of vaccines that do not require a viral vector, enhancing potential for future vaccine development.

Celsion Corporation (CLSN) reported financial results for Q2 2022, logging a net loss of $6.0 million ($0.87 per share). Operating expenses increased by 17% to $6.1 million, primarily due to rising professional fees. The company maintains a strong balance sheet with $48.1 million in cash, projecting sufficient funds into 2025. Key developments include advancements in their GEN-1 immunotherapy for ovarian cancer and the promising PLACCINE vaccine platform. The OVATION 2 study continues to progress, with complete enrollment anticipated in Q3 2022.

Celsion Corporation (NASDAQ: CLSN) announced the approval of stock options and restricted stock grants for its new CEO, Corinne Le Goff, totaling 230,000 shares. The inducement options have an exercise price of $1.95, which matches the company’s closing stock price as of July 18, 2022. These options will vest over four years, with full vesting by July 18, 2026. Celsion is focused on developing DNA-based immunotherapies and vaccines, with a pipeline that includes GEN-1 for ovarian cancer treatment. The company is committed to innovation in cancer treatment.

Celsion Corporation (NASDAQ: CLSN) announced the appointment of Corinne Le Goff, Pharm D, MBA, as President and CEO, effective July 18, 2022. Michael H. Tardugno will transition to Executive Chairman of the Board. Dr. Le Goff, with extensive experience from Moderna and Amgen, is expected to enhance Celsion's strategic direction, particularly in advancing its GEN-1 program for treating advanced-stage ovarian cancer. The company continues its focus on innovative cancer treatments and nucleic acid vaccines, aiming for significant clinical advancements.

Celsion Corporation (NASDAQ: CLSN) announced that the Data Safety Monitoring Board (DSMB) has recommended continuing the OVATION 2 Study of GEN-1 for advanced ovarian cancer after a favorable interim safety review of 87 patients. The study, which combines GEN-1 with standard chemotherapy, shows safety and tolerability, with no dose-limiting toxicities. Over 87% of the target 110 patients are enrolled, and results indicate improved surgical outcomes and chemotherapy response. The company expects to complete enrollment by Q3 2022 and plans to request FDA Breakthrough Therapy Designation.

Celsion Corporation (NASDAQ: CLSN) reported Q1 2022 results with a net loss of $10.5 million ($1.82 per share), a rise from $5.7 million ($3.31 per share) in Q1 2021. Operating expenses increased to $6.0 million, reflecting an 8% rise year-over-year. R&D expenses were $3.1 million, up 20% due to ongoing development of GEN-1 and the PLACCINE vaccine technology. Notably, 85% patient enrollment in the Phase II OVATION 2 study for ovarian cancer has been achieved, with early data showing a 27% improvement in surgical resection rates for the treatment group.